Novel Compounds that Target Estrogen Receptor (ER) Positive. Tamoxifen-resistant Breast Cancers

The drug tamoxifen is widely used to treat estrogen receptor (ER) positive breast cancer and to prevent relapse. However, half of all recurrences in breast cancer patients are resistant to tamoxifen and often, more aggressive tumors result. Recently, researchers at The Johns Hopkins University, in collaboration with the University of Maryland, have described novel compounds that have potential use for the treatment of ER positive breast cancer, in addition to other estrogen-related conditions such as vaginitis, osteoporosis, cardiovascular disease, and decreased fertility. The compounds possess a unique steroidal backbone that is essential to their specific activity against ER positive epithelial cancer cells, and cancer cells resistant to current therapies. Description (Set) Proposed Use (Set) These compounds are a novel therapy for treating tamoxifen-resistant breast cancers and can be used for other types of estrogen related conditions.

Inventor(s): Park, Ben Ho

Type of Offer: Licensing



« More Medical Patents

---